Pharma BD Deal Intelligence
Eisai built a US oncology commercial base on MGI's back, then sold off nearly every MGI-acquired asset within a decade.
Full analysis, sources & comparables →Eisai to acquire MGI Pharma at $41/share all-cash (~$3.9B), a 38.7% premium to MGI's $29.55 close on Nov 28, 2007; expected accretive to cash EPS in FY2008 and…
Bear Stearns analyst Vinay Thapar doubted other bidders would emerge to compete for MGI Pharma, since Eisai was paying cash and the premium it was offering was…
Eisai today announced the successful completion of its acquisition of MGI PHARMA for approximately $3.9 billion, integrating it as a wholly-owned subsidiary to…
Source summaries from our enrichment pipeline; follow links for originals.
All 5 sources with sentiment breakdown →
$41/share all-cash, ~$3.9B total. Oncology and acute care. Source: Eisai press release, SEC, Fierce Biotech.
Eisai built a US oncology commercial base on MGI's back, then sold off nearly every MGI-acquired asset within a decade.
Assessment window: 15yr post-close.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Eisai Co., Ltd. / MGI Pharma Inc. (this deal) | 2007 | $3.9B | 36 |
| Eisai Co., Ltd. / Ligand Pharmaceuticals (oncology product portfolio) | 2006 | $205M | 41 |
| Eisai Co., Ltd. / SEED Therapeutics Inc. | 2024 | $1.5B | — |
| Sanofi SA / Regeneron Pharmaceuticals, Inc. | 2007 | $1.0B | 97 |
| Shire plc / New River Pharmaceuticals Inc. | 2007 | $2.6B | 88 |
| Roche Holding AG / Ventana Medical Systems Inc. | 2007 | $3.4B | 88 |
| AstraZeneca PLC / MedImmune Inc. | 2007 | $15.6B | 82 |
← Browse all deals · How we score deals
More: 2007 deals · Eisai Co., Ltd. deals